Phospho-ErbB2 (HER-2) (Tyr1248) Monoclonal Antibody (PN2A), Biotin

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Phospho-ErbB2 (HER-2) (Tyr1248) Monoclonal Antibody (PN2A), Biotin

catalog :

MA5-11364

quantity :

500 uL

price :

US 622.00

clonality :

monoclonal

host :

mouse

conjugate :

biotin

antigen modification :

phosphorylated

clone name :

PN2A

reactivity :

hamsters, human, mouse, rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, blocking or activating experiments

more info or order :

Invitrogen product webpage

citations: 54

Published Application/Species/Sample/Dilution	Reference
western blot; human; 1:200; fig 1	Blancafort A, GirÃ³ Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ã, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10:e0131241 pubmed publisher
immunohistochemistry; human; 1:100	Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu Khalaf M, et al. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 2014;14:326 pubmed publisher
western blot; human; 1:250	Kirkegaard T, Hansen S, Larsen S, Reiter B, Sørensen B, Lykkesfeldt A. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014;344:90-100 pubmed publisher
immunohistochemistry; human; 1:100 western blot; human	Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm D, et al. Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS ONE. 2013;8:e79901 pubmed publisher
immunocytochemistry; human	von Schwarzenberg K, Lajtos T, Simon L, Muller R, Vereb G, Vollmar A. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Mol Oncol. 2014;8:9-19 pubmed publisher
immunoprecipitation; human immunohistochemistry; human western blot; human	Kuo H, Hsu S, Ou C, Li J, Tseng H, Chuang T, et al. Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway. Evid Based Complement Alternat Med. 2013;2013:219472 pubmed publisher
western blot; human; 1:2000	Deng X, Fogh L, Lademann U, Jensen V, Stenvang J, Yang H, et al. TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line. Tumour Biol. 2013;34:1161-70 pubmed publisher
western blot; human	Fan P, McDaniel R, Kim H, Clagett D, Haddad B, Jordan V. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer. 2012;48:3488-98 pubmed publisher
western blot; human	Cortés M, Cariaga Martínez A, Lobo M, Martín Orozco R, Motiño O, Rodríguez Ubreva F, et al. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis. 2012;33:1169-77 pubmed publisher
western blot; human	Huang X, Wang S, Lee C, Yang X, Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett. 2011;307:72-79 pubmed publisher
immunoprecipitation; human	DeFazio Eli L, Strommen K, Dao Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res. 2011;13:R44 pubmed publisher
western blot; human	Treekitkarnmongkol W, Suthiphongchai T. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol. 2010;16:4047-54 pubmed
western blot; human	Vazquez Martin A, Oliveras Ferraros C, Cufí S, del Barco S, Martin Castillo B, Menendez J. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol. 2011;226:52-7 pubmed publisher
western blot; human	Wang S, Huang X, Lee C, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene. 2010;29:4225-36 pubmed publisher
western blot; human	Huang X, Gao L, Wang S, McManaman J, Thor A, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010;70:1204-14 pubmed publisher
western blot; mouse	Liu B, Ordonez Ercan D, Fan Z, Huang X, Edgerton S, Yang X, et al. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res. 2009;7:1882-92 pubmed publisher
western blot; human	Huang X, Gao L, Wang S, Lee C, Ordentlich P, Liu B. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009;69:8403-11 pubmed publisher
immunohistochemistry; human; 1:100	Sassen A, Diermeier Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, et al. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res. 2009;11:R50 pubmed publisher
western blot; human	Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle. 2009;8:2050-6 pubmed
immunohistochemistry; mouse	Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009;28:854-65 pubmed publisher
western blot; mouse	Lewis Phillips G, Li G, Dugger D, Crocker L, Parsons K, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-90 pubmed publisher
immunohistochemistry; human; 6 ug/ml	Singer C, Hudelist G, Fuchs E, Köstler W, Fink Retter A, Gschwantler Kaulich D, et al. Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. Endocr Relat Cancer. 2009;16:73-83 pubmed publisher
western blot; human	Oda K, Okada J, Timmerman L, Rodriguez Viciana P, Stokoe D, Shoji K, et al. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008;68:8127-36 pubmed publisher
blocking or activating experiments; human; 10 ug/ml	Szabó A, Horvath G, Szollosi J, Nagy P. Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. Biophys J. 2008;95:2086-96 pubmed publisher
western blot; human; 1:200	Cortajarena A, Yi F, Regan L. Designed TPR modules as novel anticancer agents. ACS Chem Biol. 2008;3:161-6 pubmed publisher
western blot; human; 1:1000	Chakraborty A, Liang K, Digiovanna M. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res. 2008;68:1538-45 pubmed publisher
western blot; human; 2.5 ug/ml	Vazquez Martin A, Colomer R, Brunet J, Lupu R, Menendez J. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008;41:59-85 pubmed publisher
western blot; human	Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar V. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res. 2008;68:483-91 pubmed publisher
immunohistochemistry; human; 1:100	Xu S, Kitayama J, Yamashita H, Souma D, Nagawa H. Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma. J Surg Oncol. 2008;97:44-50 pubmed
western blot; human; 1:1000	Scotti M, Langenheim J, Tomblyn S, Springs A, Chen W. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2008;111:241-50 pubmed
immunohistochemistry; human; 5 ug/ml	Herbst R, Davies A, Natale R, Dang T, Schiller J, Garland L, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007;13:6175-81 pubmed
western blot; human	Martín Orozco R, Almaraz Pro C, Rodríguez Ubreva F, Cortés M, Ropero S, Colomer R, et al. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia. 2007;9:614-24 pubmed
western blot; human; 0.1 ug/ml	Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins. 2008;70:938-49 pubmed
immunohistochemistry; human; 2.5 ug/ml	Vazquez Martin A, Colomer R, Menendez J. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer. 2007;43:1117-24 pubmed
western blot; human	Liu B, Ordonez Ercan D, Fan Z, Edgerton S, Yang X, Thor A. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer. 2007;120:1874-82 pubmed
immunohistochemistry; human; 1:200	Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy J, et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer. 2007;43:725-35 pubmed
western blot; human	Xu W, Yuan X, Beebe K, Xiang Z, Neckers L. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol Cell Biol. 2007;27:220-8 pubmed
immunohistochemistry; human; 1:500	Stonecypher M, Chaudhury A, Byer S, Carroll S. Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol. 2006;65:162-75 pubmed
western blot; human; 1:200	Hansen M, Roehm P, Chatterjee P, Green S. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia. 2006;53:593-600 pubmed
flow cytometry; human	Zsebik B, Citri A, Isola J, Yarden Y, Szollosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett. 2006;104:146-55 pubmed
western blot; mouse	Kim A, Liu B, Ordonez Ercan D, Alvarez K, Jones L, McKimmey C, et al. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res. 2005;7:R708-18 pubmed
immunocytochemistry; human; 1 ug/ml immunocytochemistry; hamsters; 1 ug/ml	Friedlander E, Arndt Jovin D, Nagy P, Jovin T, Szollosi J, Vereb G. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. Cytometry A. 2005;67:161-71 pubmed
immunocytochemistry; rat	Chen J, Tseng H, Dichter M, Zhang H, Greene M. Differential localization of ErbB receptor ensembles influences their signaling in hippocampal neurons. DNA Cell Biol. 2005;24:553-62 pubmed
western blot; human	Stewart L, Lyles B, Lin M, Weigel N. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005;97:37-46 pubmed
immunohistochemistry; human	Mohsin S, Weiss H, Gutierrez M, Chamness G, Schiff R, Digiovanna M, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005;23:2460-8 pubmed
western blot; human	Menendez J, Vellon L, Mehmi I, Teng P, Griggs D, Lupu R. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene. 2005;24:761-79 pubmed
immunohistochemistry; rat; 1:600 western blot; rat	Price Schiavi S, Andrechek E, Idris N, Li P, Rong M, Zhang J, et al. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol. 2005;203:44-53 pubmed
	Menendez J, Ropero S, Lupu R, Colomer R. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells. Ann Oncol. 2004;15:1719-21 pubmed
	Mano M, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M. Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. Breast. 2004;13:347-9 pubmed
	Argiris A, Wang C, Whalen S, Digiovanna M. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res. 2004;10:1409-20 pubmed
	Hudelist G, Köstler W, Attems J, Czerwenka K, Muller R, Manavi M, et al. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer. 2003;89:983-91 pubmed
	Nielsen U, Cardone M, Sinskey A, MacBeath G, Sorger P. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci U S A. 2003;100:9330-5 pubmed
	Christensen J, Schreck R, Chan E, Wang X, Yang C, Liu L, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. 2001;7:4230-8 pubmed
	Murillo H, Schmidt L, Tindall D. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res. 2001;61:7408-12 pubmed

product information

Product Type :

Antibody

Product Name :

Phospho-ErbB2 (HER-2) (Tyr1248) Monoclonal Antibody (PN2A), Biotin

Catalog # :

MA5-11364

Quantity :

500 uL

Price :

US 622.00

Clonality :

Monoclonal

Purity :

Protein G

Host :

Mouse

Reactivity :

Human, Rat

Applications :

Immunohistochemistry: Assay-dependent, Western Blot: Assay-dependent

Species :

Human, Rat

Clone :

PN2A

Isotype :

IgG1

Storage :

4 C

Description :

ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in treatment of metastatic Her2-positive cancer, is monoclonal antibody targeting this kinase.

Immunogen :

Tyrosine-phosphorylated synthetic peptide corresponding to aa1242-1255 [Lys-TAENPE-pY-LGLDVPV] from the C-terminus of human c-erbB-2 protein (P-Tyr1248)

Format :

Liquid

Applications w/Dilutions :

Immunohistochemistry: Assay-dependent, Western Blot: Assay-dependent

Aliases :

avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; proto-oncogene c-ErbB-2; Proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)

more info or order :

Invitrogen product webpage